徐阻肺症標的治療薬の達必妥当が中国で承認された
内托体头
发表于 2024-9-27 18:05:24
141
0
0
南方財経は9月27日、セノーフィがタビト& ;reg;（度普利尤単抗注射液）中国国家薬品監督管理局（NMPA）の承認を得て、血好酸球が上昇し、制御がよくない慢性閉塞性肺疾患成人患者に用いられる。今回の承認は米国FDAの承認よりも先に行われ、EUと米国に比べて中国の承認時間が最も短く、また革新的な薬が中国人患者に恩恵を与える記録を更新した。ダビタット& ;reg;世界初の慢性肺障害標的治療薬として承認された。（21世紀経済報道）
Logomoney.com is an information publishing platform that only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
-
On October 5th, according to Southern Finance, Danish pharmaceutical company Novo Nordisk announced on Friday that it will invest 864 million Brazilian reals ($158.2 million) to renovate a factory in ...- liujingwen
- Yesterday 10:59
- Up
- Down
- Reply
- Favorite
-
On October 5th, Beijing News Beike Finance learned from Nike Group that in the first quarter of the 2025 fiscal year (as of August 31, 2024), Nike Group achieved a revenue of 11.6 billion US dollars, ...- lbxuni
- Yesterday 14:10
- Up
- Down
- Reply
- Favorite
-
On October 5th, according to Nike Group's financial report, in the first quarter of fiscal year 2025 (ending on August 31, 2024), Nike Group achieved revenue of $11.589 billion, a year-on-year decrea ...- aipipi
- Yesterday 15:14
- Up
- Down
- Reply
- Favorite
-
The three major indexes of the US stock market closed slightly higher, with the Dow Jones Industrial Average rising 0.09%, the Nasdaq rising 0.08%, and the S&P 500 index rising 0.01%. Large tech stoc ...- yzprf
- 3 Dayago
- Up
- Down
- Reply
- Favorite
